Helping improve patient outcomes and access to new medicines
Our expert team advises on commercial agreements for high cost and new drug purchases.
We advise a range of clients including NHS England when it enters into specialist and bespoke commercial arrangements relating to new and innovative high cost treatments that are not in routine commissioning.
These highly confidential commercial arrangements allow our clients to make the best possible treatments available to patients across the country whilst still delivering value for money. Pharmaceutical companies are also able to benefit from access to the world’s largest publicly funded health service.
Main Areas Of Practice
Our team regularly advises on commercial agreements for high cost and new drug purchases in the following areas:
Budget Impact Test (BIT)
If the budget impact of a new drug exceeds NICE's threshold of £20 million, in any of the first three years, NHS England may engage in commercial discussions with the company. These discussions are designed to mitigate the impact that funding the technology would have on the rest of the NHS.
Highly Specialised Technologies (HST)
HST are recommendations by NICE on the use of new and existing highly specialised medicines and treatments within the NHS in England. These medicines are often very high cost, low volume treatments where NHS England needs to enter into confidential commercial arrangements with the company in order to be able to make the treatments available to patients whilst delivering value for money to the NHS.
The 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG)
The voluntary scheme for branded medicines pricing, access and growth (VPAG) is the overarching agreement on pricing for branded medicines supplied to NHS hospitals across the UK. We have advised NHS England’s Medicines Procurement and Supply Chain team on the terms of VPAG and the preceding 2019 agreement. The deal reached means that VPAG will secure twice the level of savings of the scheme which it replaces, amounting to some £14bn in savings against list prices of medicines.
Our Clients
Our expert team specialising in high cost and new drug procurement primarily advises the Specialised Commissioning Team within NHS England.
Highlights
Our Experts
Related Expertise
BM Insights
Articles
What does the eliminating profit agenda of the Health and Social Care (Wales) Act 2025 (“the 2025 Act”) mean? On 24 March 2025, the 2025 Act received royal assent. This article...
Read MoreArticles
One of the standout points from our visit to NHS Confed Expo 2025 was the number of Voluntary, Community and Social Enterprise (VCSE) voices in the room, all of whom...
Read MoreWe were delighted to host a webinar looking at "The local authority leisure agency model in 2025 – how is the market responding to this tax efficient model and what...
Read MoreKeeping up to date with employment law developments can be difficult. Employers and HR professionals need to ensure they are well-placed to meet the challenges of constant change and to...
Read MoreBlake Morgan, RBC Brewin Dolphin, British Business Bank and Tramshed Tech co-hosted ‘Connect & Invest: Networking and Sector Spotlights from Wales & The South West’.
Read MoreKeeping up to date with employment law developments can be difficult. Employers and HR professionals need to ensure they are well-placed to meet the challenges of constant change and to...
Read More